providing answers to families affected by rare diseases
In the long and often solitary struggle of families living with rare genetic diseases, institutions sometimes find ways to formalize their commitment to the search for answers. The University of Western Australia has done so by appointing Professor Gina Ravenscroft as the inaugural Dr Patricia Kailis Chair in Rare Diseases — a position that honors a geneticist who mapped the inherited architecture of conditions like Duchenne Muscular Dystrophy, and now charges her successor with carrying that work forward. Funded through a partnership of research, philanthropic, and academic institutions, the chair is less a title than a promise: that the relatively small populations affected by rare neuromuscular diseases will not be left outside the circle of scientific attention.
- Rare diseases affect small populations but impose enormous burdens on families who often spend years without a diagnosis, let alone a treatment.
- The newly endowed chair creates a dedicated, institutionally anchored position to accelerate the discovery of rare disease genes — filling a gap that scattered, underfunded research cannot.
- Three institutions — the Harry Perkins Institute, the Stan Perron Charitable Foundation, and UWA — have pooled resources to ensure the role has lasting structural support rather than relying on short-term grants.
- Ravenscroft brings an internationally recognized track record in rare neuromuscular disease research, positioning the chair to move quickly from legacy-honoring to active scientific momentum.
- The appointment lands as a signal to affected families in Western Australia and beyond that their conditions remain a priority — and that the region is consolidating its standing as a serious hub for rare disease research.
Professor Gina Ravenscroft has been named the first holder of the Dr Patricia Kailis Chair in Rare Diseases at the University of Western Australia — a newly established endowed position within UWA's Rare Care Comprehensive Centre. The appointment, announced in late June, places one of the field's most recognized researchers at the helm of a role designed to accelerate answers for families living with conditions that are small in prevalence but vast in consequence.
The chair is jointly funded by the Harry Perkins Institute of Medical Research, the Stan Perron Charitable Foundation, and UWA, and it carries the name of Dr Patricia Verne Kailis — a geneticist who spent her career mapping the inherited basis of debilitating disorders, including Duchenne Muscular Dystrophy. Her work gave Western Australian families crucial information about their children's conditions and their own reproductive futures. Though Kailis did not live to see the chair established, her legacy now shapes the mission it carries forward.
In accepting the appointment, Ravenscroft framed it not as a personal honor but as a continuation of collaborative scientific work — acknowledging her research team, the Kailis family, and the funding institutions whose shared vision made the position possible. Her goal, she made clear, is to keep providing answers to families who have often searched for years without them.
Leaders from across the partnering institutions echoed that human-centered purpose. UWA's Deputy Vice-Chancellor for Research, Professor Anna Nowak, pointed to Ravenscroft's global track record as evidence of the kind of excellence the university seeks to support. Peter Leedman of the Harry Perkins Institute described the appointment as a deepening of the sector's collective commitment, while Gareth Baynam and Elizabeth Perron highlighted Ravenscroft's passion for building rare disease expertise in the region. Together, the appointment signals that for families affected by rare neuromuscular conditions, the search for answers will continue — now with renewed and formally anchored institutional resolve.
Professor Gina Ravenscroft, whose work on rare neuromuscular diseases has earned her recognition across the global research community, has been named the first holder of the Dr Patricia Kailis Chair in Rare Diseases at the University of Western Australia. The appointment, announced in late June, places her at the helm of a newly established endowed position within UWA's Rare Care Comprehensive Centre—a role designed to accelerate the hunt for answers to conditions that affect relatively small populations but carry enormous weight for the families living with them.
The chair itself is a collaborative creation, funded jointly by three institutions: the Harry Perkins Institute of Medical Research, the Stan Perron Charitable Foundation, and UWA. Its purpose is direct and human-centered: to improve the lives of families and children touched by rare diseases, with particular focus on genetic conditions that have long resisted easy diagnosis or treatment. The position carries the name of Dr Patricia Verne Kailis, a geneticist whose career was defined by pioneering work in mapping debilitating inherited disorders. She mapped the genetic basis of Duchenne Muscular Dystrophy, among other conditions, providing crucial information to Western Australian families trying to understand their children's futures and make informed reproductive decisions. Kailis died before seeing this chair established in her name, but her legacy now anchors the work that will unfold within it.
Ravenscroft, in her remarks upon the appointment, emphasized that rare disease research is fundamentally collaborative work. She acknowledged the Kailis family, the foundations, and the university for their vision in creating the position, and she spoke of her gratitude to her own research team—past and present—whose dedication has made her discoveries possible. She framed the appointment not as an individual honor but as an opportunity to continue a particular kind of scientific mission: providing answers to families who have often spent years searching for diagnosis and understanding.
The University of Western Australia's Deputy Vice-Chancellor for Research, Professor Anna Nowak, positioned the appointment within the institution's broader commitment to tackling serious health challenges. Ravenscroft's track record of globally significant discoveries, Nowak noted, demonstrates the kind of excellence the university aims to support and amplify. The appointment signals alignment between the researcher's ambitions and the institution's strategic priorities around innovation and community impact in medical research.
Peter Leedman, who leads the Harry Perkins Institute, described the appointment as a strengthening of the institute's commitment to rare disease research and a deepening of collaboration across the sector. He emphasized that the real measure of success will be impact on individuals and families living with these conditions—the relentless pursuit of rare disease genes that might unlock new treatments or preventive strategies. Gareth Baynam, Medical Director of the Rare Care Comprehensive Centre, and Elizabeth Perron, Chair of the Stan Perron Charitable Foundation, both highlighted Ravenscroft's demonstrated passion for expanding rare disease expertise within Western Australia, a region that has become a notable hub for this kind of research.
The appointment represents a convergence of several forces: a researcher at the height of her influence, institutional commitment backed by philanthropic funding, and a clear mandate to honor a predecessor's legacy while pushing the field forward. For families affected by rare neuromuscular conditions, the chair's establishment signals that their struggles have not been forgotten by the research community—and that the search for answers will continue with renewed institutional support.
Notable Quotes
Medical research is very much a team effort and perhaps nowhere is this truer than in rare diseases.— Professor Gina Ravenscroft
Her appointment underlines the University's commitment to addressing serious health challenges and aligns with our vision to drive innovation, excellence and community impact in medical research.— Professor Anna Nowak, UWA Deputy Vice-Chancellor (Research)
The Hearth Conversation Another angle on the story
Why does naming a chair after someone who has passed matter so much in research?
It anchors the work to a particular vision and set of values. Dr Kailis spent her career giving families answers about genetic diseases. By naming this chair after her, the institutions are saying: this is the kind of work we commit to, this is the legacy we're extending.
What makes rare disease research different from studying more common conditions?
Scale and isolation. With a common disease, you have thousands of patients, funding flows more readily, and researchers can build on each other's work. Rare diseases often mean a handful of families, scattered geographically, searching for years just to get a diagnosis. The research is harder to fund and harder to do—but the impact on those families is absolute.
Ravenscroft mentioned that rare disease work is a team effort. Why is that especially true here?
Because you need geneticists, clinicians, lab technicians, and often the families themselves contributing their medical histories and genetic samples. No single person can map a disease gene or develop a treatment alone. The collaboration is built into the science.
What does "translational impact" mean in this context?
It means moving from discovery in the lab to something that actually helps patients—a diagnostic test, a treatment, a way to prevent the disease. It's the bridge between pure research and real-world medicine.
Why would the Stan Perron Charitable Foundation fund this alongside a research institute and a university?
Because rare diseases affect families, and families need more than just research—they need clinical care, genetic counseling, support networks. By funding through multiple institutions, they're building a more complete ecosystem around the problem.